Allena Pharmaceuticals Announces Rescheduling of
Special Meeting
to Approve Reverse Stock Split
NEWTON, Mass., July 5, 2022 (GLOBE NEWSWIRE)
— Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a
late-stage, biopharmaceutical company dedicated to developing and
commercializing first-in-class, oral enzyme
therapeutics to treat patients with rare and severe metabolic and
kidney disorders, today announced that it has rescheduled its
special meeting, which was scheduled for July 5, 2022, to,
among other things, consider and vote on a proposed amendment to
its amended and restated certificate of incorporation, as amended,
in order to effect a reverse stock split of its issued and
outstanding common stock.
The date of the rescheduled special meeting, and the new record
date for determining the Allena stockholders entitled to vote
thereat, will be determined in the near future, and will be will be
included in supplemental proxy materials to be filed with the SEC
and distributed to stockholders promptly after the new record
date.
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to discovering, developing and commercializing
first-in-class, oral biologic
therapeutics to treat patients with rare and severe metabolic and
kidney disorders.
Additional Information and Where to Find It
In connection with the special meeting described above the Company
filed a definitive proxy statement with the Securities and Exchange
Commission on May 24, 2022 and in connection with the
rescheduled meeting the Company will file with the Securities and
Exchange Commission a supplement to the definitive proxy statement.
This press release does not contain all the information that should
be considered concerning the matters to be considered at the
special meeting, including the proposed reverse stock split, and is
not intended to form the basis of any investment decision or any
other decision in respect of such matters
The Company’s stockholders and other interested persons are advised
to read the definitive proxy statement and, when available, the
proxy supplement, and any amendments thereto, and any other
documents filed in connection with the matters to be considered at
the special meeting, including the proposed reverse stock split, as
these materials will contain important information about the
Company and such matters. The Company’s stockholders will also be
able to obtain copies of these documents filed with the SEC,
without charge, once available, at the SEC’s website at
www.sec.gov, or by directing a request to the Company’s corporate
secretary /o Allena Pharmaceuticals, Inc., One Newton Executive
Park, Suite 202, Newton, MA 02462.